Janus Henderson Investors
Asset Management / Growth InvestorJanus Henderson Investors, United Kingdom (head office)See on the mapjanushenderson.com
Janus Henderson Investors is a global asset management firm serving clients worldwide. It invests across equities, fixed income, alternatives, and multi-asset strategies.
- 3
- Portfolio companies on reccy
- 0
- Hiring now
- 0
- Open roles in the portfolio
- Nov 2026
- Latest portfolio round
Hiring now in the portfolio0
Apply on each company's siteNone of their companies on reccy has an open role right now. Browse all neurotech roles
Portfolio on reccy3
From company funding records- Series B · $105M · Nov 2026None
NeuroStim Solutions
United States · Led a round · Series B · $105M · Nov 2026
- Series B · $125M · Apr 2026None
Ray Therapeutics
San Diego, CA · Led a round · Series B · $125M · Apr 2026
- Series C · $100M · Sep 2025None
Galvanize Therapeutics, Inc.
Redwood City, CA · Led a round · Series C · $100M · Sep 2025
Their companies, round by round
From company funding records- NeuroStim SolutionsUnited States
Neuromodulation
- Nov 2026Series B · $105MLed
- Oct 2023Series A · $5.8M
- Oct 2023Undisclosed · $10M
- Jul 2023Grant (prize money) · $1.8M
- Ray TherapeuticsSan Diego, CA
Neuroscience research tools · Sensory restoration
- Sep 2026Grant · $8M
- Apr 2026Series B · $125MLed
- Apr 2025Grant · $8M
- Nov 2023Grant · $4M
- May 2023Series A · $100M
- Apr 2022Grant · $4M
- Galvanize Therapeutics, Inc.Redwood City, CA
- Nov 2026Series D · $130M
- Sep 2025Series C · $100MLed
- Sep 2022Series B · $100M
- Mar 2022Debt · $4M
- Mar 2022Series A · $3.4M
- Mar 2022Debt · $2M
Rounds marked Led list Janus Henderson Investors as a lead investor; the rest are the company's other funding.
Recent rounds in the portfolio
- Nov 2026
NeuroStim Solutions · Series B $105MLead
With Perceptive Advisors, RTW Investments, Affinity Asset Advisors, Google Ventures
- Apr 2026
Ray Therapeutics · Series B $125MLead
- Sep 2025
Galvanize Therapeutics, Inc. · Series C $100MLead
With Sofinnova Partners, Norwest Venture Partners, Elevage Medical Technologies, Ally Bridge Group, Perceptive Xontogeny Venture Fund, Longaeva, Fidelity Management & Research Company, T. Rowe Price Associates, Gilmartin Capital, Apple Tree Partners
Portfolio in the news
From the Cortex · last 12 months- Oct 2026
- Sep 2026